Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  TransMedics Group, Inc.    TMDX

TRANSMEDICS GROUP, INC.

(TMDX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2020 11/20/2020 11/23/2020 11/24/2020 11/25/2020 Date
14.23(c) 14.78(c) 14.16(c) 14.51(c) 14.6(c) Last
23 773 82 887 89 572 123 209 63 851 Volume
+0.28% +3.87% -4.19% +2.47% +0.62% Change
More quotes
Financials (USD)
Sales 2020 24,0 M - -
Net income 2020 -29,1 M - -
Net cash position 2020 95,9 M - -
P/E ratio 2020 -12,2x
Yield 2020 -
Sales 2021 48,6 M - -
Net income 2021 -17,8 M - -
Net cash position 2021 73,2 M - -
P/E ratio 2021 -21,7x
Yield 2021 -
Capitalization 397 M 397 M -
EV / Sales 2020 12,5x
EV / Sales 2021 6,65x
Nbr of Employees 109
Free-Float 88,2%
More Financials
Company
Transmedics group, Inc. is a commercial-stage medical technology company. It is focused on developing organ transplant therapy for end-stage organ failure patients across multiple disease states. The Company has designed and developed organ care system (OCS) a portable organ perfusion, optimization and monitoring system that utilizes customized technology to replicate near-physiologic conditions for donor organs... 
More about the company
Notations Surperformance© of TransMedics Group, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about TRANSMEDICS GROUP, INC.
11/06TRANSMEDICS : Management's Discussion and Analysis of Financial Condition and Re..
AQ
11/04TRANSMEDICS : 3Q Earnings Snapshot
AQ
11/04TRANSMEDICS GROUP, INC. : Results of Operations and Financial Condition, Financi..
AQ
11/04TRANSMEDICS : Reports Third Quarter 2020 Financial Results
PR
10/29TRANSMEDICS : to Participate in Upcoming Virtual Investor Conferences
PR
10/21TRANSMEDICS : to Report Third Quarter 2020 Financial Results on November 4, 2020
PR
09/28TRANSMEDICS : Announces Temporary Postponement of OCS Heart FDA Advisory Panel C..
AQ
09/28TransMedics Announces Temporary Postponement of OCS Heart FDA Advisory Panel ..
GL
09/01TransMedics to Present at the 18th Annual Morgan Stanley Global Healthcare Co..
GL
08/13TRANSMEDICS : Corporate Overview
PU
08/10TRANSMEDICS : Management's Discussion and Analysis of Financial Condition and Re..
AQ
08/06TRANSMEDICS : 2Q Earnings Snapshot
AQ
08/05TRANSMEDICS GROUP, INC. : Results of Operations and Financial Condition, Financi..
AQ
08/05TransMedics Reports Second Quarter 2020 Financial Results
GL
05/07TRANSMEDICS : 1Q Earnings Snapshot
AQ
More news
News in other languages on TRANSMEDICS GROUP, INC.
02/26TRANSMEDICS GROUP, INC. : Veröffentlichung des Jahresergebnisses
02/26TRANSMEDICS GROUP, INC. : publication des résultats annuels
More news
Chart TRANSMEDICS GROUP, INC.
Duration : Period :
TransMedics Group, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TRANSMEDICS GROUP, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 19,20 $
Last Close Price 14,60 $
Spread / Highest target 71,2%
Spread / Average Target 31,5%
Spread / Lowest Target 2,74%
EPS Revisions
Managers
NameTitle
Waleed H. Hassanein President, Chief Executive Officer & Director
James R. Tobin Chairman
John F. Carey Vice President-Operations
Stephen Gordon Chief Financial Officer, Secretary & Treasurer
Phillip Camp Chief Medical Officer
Sector and Competitors